Donal O'Gorman

The NICB (National Institute for Cellular Biotechnology) is a leading research institute located on the DCU campus in Dublin. The NICB is a major focus for cell and molecular biology research in Ireland, in particular as it interacts with clinical translational research in the cancer, diabetes and ocular disease areas, and with the Biopharma and other bioscience-related industry.

The Irish Endocrine Society (IES) promotes the development of education, research and clinical excellence in endocrinology on the island of Ireland. The membership comprises clinicians and scientists that have a specific interest in endocrinology and diabetes.

The 3U Diabetes Partnership is a major strategic initiative that combines the research expertise of two research intensive, non-medical Universities (Dublin City University, NUI Maynooth) in the Dublin region with Ireland’s largest medical school (Royal College of Surgeons Ireland) and its associated hospital based Clinical and Translational Research Centres. The mission of the TRH is to address the unmet needs in the treatment of diseases and focus on an output that is targeted towards delivery. It will not only play an important role in advancing biomedical science, but will also deliver key innovations to the industry sector which is of critical importance to our economy. The 3U Diabetes Partnership is a multi-disciplinary research consortium comprising clinicians and researchers that (i) undertake novel inter-disciplinary research to create novel treatment and preventive approaches and (ii) improve the clinical management of patients with diabetes. We have developed an integrated translational research model, designed to facilitate industry partners, by providing a single interface for diabetes research in Ireland.

The Centre for Preventive Medicine (CPM) at Dublin City University is a unique research centre aimed at preventing or delaying the morbidity and mortality associated with common chronic diseases. The CPM focuses on diabetes, cardiovascular disease, respiratory disease and musculoskeletal disorders. We integrate basic, translational and applied research to reduce the development and progression of disease through: (i) Human Translational Research to identify novel responses to disease intervention and translate promising basic research findings into effective preventive or therapeutic strategies. (ii) Cell and Molecular Physiology to provide a basic science approach to understanding the pathophysiology and progression of disease as well as identifying novel therapeutic targets (iii) Population Health to develop, modify and implement effective evidence based interventions. Together, clinicians and scientists in the CPM work together to: (i) identify early biological markers of disease (ii) develop effective physiological, behavioural and pharmacological interventions (iii) investigate cellular and molecular mechanisms of disease pathophysiology (iv) implement hospital and community-based prevention programmes.

In this course you will learn practical information about entrepreneurship guided by expert participants in the Silicon Valley startup ecosystem, delivered by a preeminent life sciences/medical institution, the University of California San Francisco (UCSF). The content is focused on startups that can have the potential to positively impact human health at scale. The course caters for interests in therapeutics, medical devices, diagnostics or healthtech/digital health.